Combined oral supplementation with magnesium plus vitamin D alleviates mild to moderate depressive symptoms related to long-COVID: an open-label randomized, controlled clinical trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Individuals with long-COVID exhibit a higher frequency of hypomagnesemia, vitamin D deficiency, and depression.

Using the Beck Depression Inventory (BDI), diagnosis of MMD was established based on a score of ≥11<30.

Who Took Part

The abstract describes 60 subjects taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

A total of 60 subjects, aged 52.8±12.6 years, with a diagnosis of hypomagnesemia, vitamin D deficiency, and mild-to-moderate depression (MMD) related to long-COVID, were enrolled in an open-label randomized, controlled clinical trial.

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

Using the Beck Depression Inventory (BDI), diagnosis of MMD was established based on a score of ≥11<30.

PubMed files the paper under topics including Vitamin D, Depression, Dietary Supplements, COVID-19, Magnesium, SARS-CoV-2 and Magnesium Chloride.

The authors tagged it with the keywords long-COVID.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 60 subjects.

The publication is from 2024 (Magnesium research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.